U.S. markets open in 4 hours 59 minutes
  • S&P Futures

    4,476.00
    +1.75 (+0.04%)
     
  • Dow Futures

    34,799.00
    +50.00 (+0.14%)
     
  • Nasdaq Futures

    15,519.25
    +1.50 (+0.01%)
     
  • Russell 2000 Futures

    2,228.90
    +1.00 (+0.04%)
     
  • Crude Oil

    72.02
    -0.59 (-0.81%)
     
  • Gold

    1,762.50
    +5.80 (+0.33%)
     
  • Silver

    23.02
    +0.23 (+0.99%)
     
  • EUR/USD

    1.1781
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.51
    +0.33 (+1.82%)
     
  • GBP/USD

    1.3807
    +0.0010 (+0.08%)
     
  • USD/JPY

    109.9160
    +0.1980 (+0.18%)
     
  • BTC-USD

    47,950.67
    -179.97 (-0.37%)
     
  • CMC Crypto 200

    1,225.10
    -8.19 (-0.66%)
     
  • FTSE 100

    7,054.27
    +26.79 (+0.38%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

ResMed (RMD) Moves 6% Higher: Will This Strength Last?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ResMed RMD shares ended the last trading session 6% higher at $231.70. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.9% gain over the past four weeks.

ResMed scored a strong price increase after the company’s peer in the field of sleep apnea devices, Koninklijke Philips issued recall notification for a series of its sleep and respiratory care devices. Many of the analysts think that Philips being in a tight spot will lead to a shift in customer demand toward ResMed competitive products.

This maker of medical products for respiratory disorders is expected to post quarterly earnings of $1.28 per share in its upcoming report, which represents a year-over-year change of -3.8%. Revenues are expected to be $778.1 million, up 1% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For ResMed, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RMD going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.